Pharmacology · Diabetes Pharmacology

Insulin Pharmacology

Mechanisms, preparations, dosing, and adverse effects

Glucose-stimulated insulin secretion is a K-ATP channel-dependent process: glucose enters the beta cell via GLUT-2 and is metabolized by glucokinase, raising the ATP/ADP ratio, which closes K-ATP channels, depolarizes the membrane, triggers calcium influx, and causes insulin granule exocytosis — sulfonylureas exploit this same pathway by closing K-ATP channels independently of glucose, which is why they cause hypoglycemia even when blood glucose is normal.
Insulin preparation classes are differentiated by onset and duration of action, which are engineered through structural modifications to human insulin: rapid-acting analogues (lispro, aspart, glulisine) invert the B-chain C-terminal residues to prevent hexamer formation, giving 10–15 minute onset; long-acting analogues (glargine, detemir, degludec) use different mechanisms — glargine forms microprecipitates at physiological pH, detemir uses fatty acid albumin binding, and degludec forms multi-hexamer chains — all producing peakless 20–42 hour duration.
Regular insulin is the only insulin formulation safe for intravenous use — all other preparations (NPH, long-acting analogues, rapid-acting analogues) are formulated with zinc, protamine, or albumin-binding modifications that make IV administration dangerous or unpredictable; this is clinically critical in the surgical and ICU setting where IV insulin drips are standard.
The NICE-SUGAR trial established that intensive glucose control (81–108 mg/dL) in critically ill patients increased 90-day mortality compared to conventional control (140–180 mg/dL) — the benefit once predicted for tight glycemic control was eliminated by severe hypoglycemia risk; current targets in critical care are 140–180 mg/dL, with hypoglycemia defined as below 70 mg/dL requiring immediate intervention.
Insulin requirements change dramatically across physiological states: they double in the third trimester of pregnancy due to human placental lactogen-driven insulin resistance, fall abruptly at delivery, increase with glucocorticoid use (peaking in the afternoon due to glucocorticoid timing), and decrease with renal impairment (reduced insulin clearance prolongs duration of action and significantly increases hypoglycemia risk below eGFR 30 mL/min).

Abbreviations: GLUT-2 = glucose transporter 2 · K-ATP = ATP-sensitive potassium channel · NPH = neutral protamine Hagedorn · GLP-1 = glucagon-like peptide-1 · NICE-SUGAR = Normoglycemia in Intensive Care Evaluation and Surviving Using Glucose Algorithm Regulation · eGFR = estimated glomerular filtration rate · IV = intravenous · ICU = intensive care unit

Beta Cell Glucose-Stimulated Insulin Secretion

Physiological Mechanism

K-ATP Channel Cascade

Glucose enters via GLUT-2

→

Glucokinase metabolizes glucose

→

ATP/ADP ratio rises

→

K-ATP channel closes

→

Membrane depolarizes

→

Ca²⁺ influx → Insulin secreted

Sulfonylureas close K-ATP channels independent of glucose — identical downstream effect, hence hypoglycemia even when blood glucose is normal.

Insulin Preparations — Pharmacokinetic Profiles

Class	Examples	Onset	Peak	Duration / Key Point
Rapid	Lispro, aspart, glulisine	10–15 min	1–2 hr	3–5 hr; inject at mealtime; mealtime bolus dosing
Short	Regular insulin	30–60 min	2–3 hr	5–8 hr; the only insulin safe for IV use
Intermediate	NPH (neutral protamine Hagedorn)	1–2 hr	4–8 hr	12–18 hr; nocturnal hypoglycemia risk; less preferred than long-acting
Long	Glargine, detemir, degludec	1–2 hr	Peakless	20–42 hr; once-daily basal coverage; degludec has longest duration (~42 hr)

Receptor Signaling and Adverse Effects

Downstream Effects

Insulin Receptor Signaling

Muscle and fat: GLUT-4 vesicle translocation to cell surface → glucose uptake; the primary mechanism of postprandial glucose disposal
Liver: glycogen synthesis increased, gluconeogenesis and glycogenolysis suppressed
Adipose tissue: lipolysis inhibited, free fatty acid release reduced
All tissues: amino acid uptake and potassium uptake promoted — hypokalemia can occur with high-dose insulin

Toxicity and Interactions

Adverse Effects

Hypoglycemia: most dangerous adverse effect; rule of 15 — 15 g fast-acting carbohydrates, recheck in 15 minutes
Weight gain 2–6 kg with intensification — consider GLP-1 agonist or SGLT-2 inhibitor co-therapy
Lipohypertrophy at injection sites → erratic insulin absorption; rotate injection sites systematically
Beta-blockers: mask tachycardia response to hypoglycemia; prolong recovery by blocking glycogenolysis
Glucocorticoids: increase insulin requirements significantly — afternoon glucose most affected (timing effect)
Alcohol: inhibits hepatic gluconeogenesis → delayed hypoglycemia, especially with skipped meals

Clinical Pearls — Special Populations

Obstetrics

Pregnancy

Insulin is the only proven-safe antihyperglycemic agent in pregnancy — does not cross the placenta
Lispro and aspart are the preferred rapid-acting agents — most safety data in pregnancy
Requirements double by the third trimester due to human placental lactogen-induced insulin resistance
Fall abruptly at delivery — reduce dose immediately post-partum to avoid hypoglycemia

Critical Care / Perioperative

Inpatient Use

Target glucose: 140–180 mg/dL in critically ill patients (NICE-SUGAR evidence)
NICE-SUGAR trial: intensive control 81–108 mg/dL increased 90-day mortality — do not target near-normoglycemia in ICU
Basal insulin at 75–80% of usual home dose; bolus held while patient is NPO (nothing by mouth)
Intravenous regular insulin preferred for major surgery or ICU — rapid titratability

Kidney Disease

Renal Impairment

Reduced insulin clearance prolongs duration of action as eGFR falls — same dose lasts longer
Dose reduction required when eGFR falls below 30 mL/min — hypoglycemia risk increases significantly
Monitor blood glucose more frequently in progressive CKD — insulin requirements are not static
Degludec and detemir: more predictable in renal impairment than NPH, which has variable absorption

Hypoglycemia Management — Rule of 15

For conscious patients with blood glucose below 70 mg/dL: administer 15 grams of fast-acting carbohydrates (4 ounces juice, glucose tablets, or similar), wait 15 minutes, and recheck blood glucose. If still below 70 mg/dL, repeat. Once glucose is above 70 mg/dL, follow with a protein-containing snack to prevent recurrence. For unconscious or unable-to-swallow patients: administer 1 mg glucagon intramuscularly or intranasally (GlucaGen, Baqsimi), or 50 mL of 50% dextrose intravenously. Beta-blockers blunt the tachycardia warning sign and prolong recovery by impairing glycogenolysis — patients on beta-blockers require lower hypoglycemia thresholds for intervention.

Suggested References

Author / Source	Title	Publication
Katzung BG, ed.	Basic and Clinical Pharmacology, 15th ed. — Chapter 41: Pancreatic Hormones and Antidiabetic Drugs	McGraw-Hill; 2021
Brunton L, Knollmann B, Hilal-Dandan R, eds.	Goodman & Gilman's The Pharmacological Basis of Therapeutics, 14th ed. — Chapter 45: Endocrine Pancreas and Pharmacotherapy of Diabetes Mellitus and Hypoglycemia	McGraw-Hill; 2023
Saltiel AR, Kahn CR	Insulin signalling and the regulation of glucose and lipid metabolism	Nature. 2001;414(6865):799–806
Rorsman P, Braun M	Regulation of insulin secretion in human pancreatic islets	Annu Rev Physiol. 2013;75:155–179
Nauck MA, Meier JJ	Incretin hormones: their role in health and disease	Diabetes Obes Metab. 2018;20(Suppl 1):5–21
Korenblat KM et al	Liver, muscle, and adipose tissue insulin action is directly related to intrahepatic triglyceride content in obese subjects	Gastroenterology. 2008;134(5):1369–1375
Hirsch IB	Insulin analogues	N Engl J Med. 2005;352(2):174–183
Havelund S et al	The mechanism of protraction of insulin detemir, a long-acting, acylated analog of human insulin	Pharm Res. 2004;21(8):1498–1504
Becker RHA et al	New insulin glargine 300 Units/mL provides a more even activity profile and prolonged glycemic control at steady state	Diabetes Care. 2015;38(4):637–643
Frid AH et al	New insulin delivery recommendations	Mayo Clin Proc. 2016;91(9):1231–1255
Duckworth WC, Bennett RG, Hamel FG	Insulin degradation: progress and potential	Endocr Rev. 1998;19(5):608–624
Riddle MC et al	The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients	Diabetes Care. 2003;26(11):3080–3086
American Diabetes Association	Standards of Care in Diabetes—2024	Diabetes Care. 2024;47(Suppl 1):S1–S321
NICE-SUGAR Study Investigators	Intensive versus conventional glucose control in critically ill patients	N Engl J Med. 2009;360(13):1283–1297
Cryer PE	Mechanisms of hypoglycemia-associated autonomic failure in diabetes	N Engl J Med. 2013;369(4):362–372
Heise T et al	Ultra-long-acting insulin degludec has a flat and stable glucose-lowering effect in type 2 diabetes	Diabetes Obes Metab. 2012;14(10):944–950
Blumer I et al	Diabetes and pregnancy: an Endocrine Society clinical practice guideline	J Clin Endocrinol Metab. 2013;98(11):4227–4249